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Martina B. Lorey,5 Jari Metso,6,9 Katariina Öörni,5 Samantha J. King,4,7 Oommen P. Oommen,8
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Helsinki Institute for LifeSUMMARY
High-density lipoproteins (HDLs) are a group of different subpopulations of sialy-
lated particles that have an essential role in the reverse cholesterol transport
(RCT) pathway. Importantly, changes in the protein and lipid composition of
HDLs may lead to the formation of particles with reduced atheroprotective prop-
erties. Here, we show that Streptococcus pneumoniae pneumolysin (PLY) and
neuraminidase A (NanA) impair HDL function by causing chemical and structural
modifications of HDLs. The proteomic, lipidomic, cellular, and biochemical anal-
ysis revealed that PLY and NanA induce significant changes in sialic acid, protein,
and lipid compositions of HDL. The modified HDL particles have reduced choles-
terol acceptor potential from activated macrophages, elevated levels of malon-
dialdehyde adducts, and show significantly increased complement activating
capacity. These results suggest that accumulation of thesemodifiedHDLparticles
in the arterial intima may present a trigger for complement activation, inflamma-
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Streptococcus pneumoniae is an important pathogen that typically causes otitis media, sinusitis, pneu-
monia, and more rarely severe infections such as sepsis and meningitis. Despite the availability of vaccines,
pneumococcus is still one of the most common causes of hospitalization in adults, especially the elderly
(Gil-Prieto et al., 2016). S. pneumoniae possesses virulence factors such as pneumolysin (PLY) and neur-
aminidase A (NanA). PLY is a cholesterol-dependent cytolysin that lyses human cells, while NanA removes
terminal sialic acids including those on host cell surfaces and sensitizes cells for attack by PLY (Burnaugh
et al., 2008; Kanclerski and Mollby, 1987; Syed et al., 2019).
The role of cellular cholesterol efflux mediated by high-density lipoprotein (HDL) is crucial to prevent for-
mation of foam cells, generation of pro-inflammatory macrophages, and inflammation, all of which play a
crucial role in the pathogenesis of atherosclerosis (Paoletti et al., 2004). HDL also possesses anti-inflamma-
tory activities and binds and neutralizes microbial molecules such as lipopolysaccharides (LPSs) and
lipoteichoic acids (Blauw et al., 2020; Gordon et al., 2011; Khovidhunkit et al., 2004; Pirillo et al., 2015a).
Importantly, inflammation caused by acute microbial infection or coronary artery disease launches signif-
icant changes in lipid metabolism and in the protein and lipid composition of HDL. These chemical,
compositional, and structural changes can transform atheroprotective HDL into dysfunctional pro-athero-
genic and pro-inflammatory particles with attenuated cholesterol acceptor and anti-inflammatory activities
(Pirillo et al., 2015b; Smith, 2010). This suggests a role for microbial molecules in modifying the anti-inflam-
matory effects of HDL. The two main subfractions of HDL, HDL-2 and HDL-3, differ in their density, size,
protein, and lipid composition (Kaji, 2013). Of these, HDL-2 is more susceptible to oxidation, and the re-
sulting modifications may impair its function in mediating cellular cholesterol efflux (Paavola et al., 2017).
We show here that S. pneumoniae PLY andNanA interact with HDL. Binding of PLY to HDL leads to reduced
PLY and NanA-mediated hemolytic activity and simultaneously to formation of modified HDL particles that
display changed protein, lipid, and sialic acid composition which are associated with cardiovasculariScience 24, 102535, June 25, 2021 ª 2021 The Author(s).
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Figure 1. Interaction between HDL and S. pneumoniae molecules PLY and NanA reduces PLY-mediated cytolysis and leads to HDL modification
ex vivo
(A) THP-1 cells incubated with increasing concentrations of HDL-2 with or without 100 nM PLY or 100 nM PLY and 800 nM NanA. LukS was used as a negative
control for cell lysis. Permeability is shown as the percentage of cells staining positive for 40,6-diamidino-2-phenylindole in flow cytometry. See also Figures
S1A and S1B.
(B) Human red blood cells incubated with 10 nM PLY and 800 nMNanA. The effect of HDL-2 on the lytic activity of PLY was tested by the addition of increasing
concentrations of HDL-2. Cholesterol-mediated inhibition was analyzed with increasing concentrations of liposomes. A sample with only HDL-2 was used as
a negative control.
(C) Enzyme-linked immunosorbent assay indicating binding of PLY to HDL-2. See also Figures S1C and S1D.
(D) Western blot of total HDL samples, isolated from plasma, incubated with (HDL + PLY) or without PLY (HDL). PLY control shows the size of the PLY
monomer and dimer in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
(E) Total HDL samples isolated from ex vivo experiment analyzed by MS/MS. See also Table S1. Numbers are shown as the percentage of peptide spectrum
matches (PSMs) of all identified proteins with a score of >10 or PSMs >4 in the HDL sample. Increase or reduction in the protein content in plasma-isolated
HDL samples from the blood incubated with PLY and NanA compared to the sample without microbial molecules is marked with arrows. The detected
statistically significant differences (p < 0.05) between highest and lowest ([A] and [B]) HDL or (C) PLY concentrations were calculated using one-way analysis of





Articlediseases (Cardner et al., 2020; Okada et al., 2019). These modified HDL particles are more susceptible to
complement attack and possess reduced capacity to mediate cholesterol efflux. These results provide a
novel explanation of how microbial infections could be linked to atherosclerosis by modifying HDL and
potentially reducing its atheroprotective properties.RESULTS
HDL inhibits PLY cytolytic activity
Because HDL is known to bind to several microbial molecules (Figueiredo et al., 2003; Levine et al., 1993;
Surewaard et al., 2012), we analyzed whether HDL could inhibit PLY-mediated hemolysis. While NanA
increased PLY-mediated lysis especially on white blood cells (Figures S1A and S1B), the cytolytic effect
of PLY and NanA on both human red and white blood cells was significantly inhibited by the addition of
HDL-2 (Figures 1A and 1B). Similarly, the presence of cholesterol-containing liposomes caused dose-
dependent inhibition of PLY-mediated hemolysis. These results suggest that the inhibitory effect of
HDL-2 on PLY hemolytic activity is due to the interaction of PLY with HDL surface unesterified choles-
terol, which would reduce binding of the toxin to cell surfaces, thereby reducing PLY-mediated
hemolysis.HDL interaction with PLY and NanA leads to HDL modification ex vivo
To understand the mechanism behind the HDL-2-mediated inhibition of PLY, we first analyzed whether
PLY binds to HDL. As we expected, PLY but not NanA bound to HDL-2 in a dose-dependent fashion (Fig-
ure 1C). Interestingly, PLY bound less to rabbit HDL, indicating species specificity of this toxin as
observed for other cytolysins (Figure S1C) (Nagamune et al., 1997; Spaan et al., 2017). Binding of PLY
to HDL also showed subclass specificity since it bound significantly less to HDL-3 than to HDL-2 (Fig-
ure S1D). Also, ex vivo binding of both the PLY monomer and dimer was detected on the isolated total
HDL fraction (Figure 1D) indicating PLY oligomerization (Gilbert et al., 1998). The presence of PLY and
absence of NanA on the isolated HDL particles from the ex vivo assay was verified by mass spectrometry
(MS). An absence of C4B in the PLY-treated samples further verified specific binding of PLY to the 3b-hy-
droxyl group of cholesterol which is the ligand for both complement C4B and cholesterol-dependent cy-
tolysins (Law et al., 1984) (Figure 1E and Table S1). The proteomic profiles also revealed differences be-
tween the HDL particles isolated from plasma that were incubated with or without PLY and NanA.
Increases in hemoglobin subunits and complement C3 reflected lytic function of PLY and susceptibility
of the HDL to complement mediated attack, respectively. In contrast, the reduction in serum paraoxo-
nase (PON-1) and increase in serum amyloid A1 indicated the loss of functionality and cardioprotective
effects of HDL (Shao and Heinecke, 2018).
Incubation of HDL with NanA resulted in the release of terminal sialic acids from HDL as detected by
loss of binding of the sialic acid-binding lectin MALII and by the detection of free sialic acids (Figures
2A and 2B). These results suggest that HDL particles are susceptible to the enzymatic activity of NanA.
To further understand the concerted function of PLY and NanA in HDL modification, we coated HDL
with monosialotetrahexosylganglioside (GM1). The presence of GM1 on HDL-2 significantly reducediScience 24, 102535, June 25, 2021 3
Figure 2. NanA activity exposes HDL-2 for PLY binding
(A) Absence of sialic acids on HDL-2 incubated with NanA shown by loss of binding ofMALII in microscale thermophoresis (affinity 1469 nM in the presence of
sialic acids).
(B) Release of free sialic acid in the presence of NanA. Release of sialic acids is calculated as the percentage of maximum absorbance measured without
NanA.
(C) Increasing concentrations of GM1 inhibit PLY binding to HDL-2.
(D) NanA treatment of HDL-2 with 6 mM GM1 causes a concentration-dependent increase in PLY binding (GM1+PLY).
(E) HDL-2 without GM1 (buffer + PLY) shows no increase in PLY binding. HDL-2 with (GM1) or without GM1 and PLY (buffer) shows no binding of NanA. The
detected statistical significance (p < 0.05) the between highest and lowest (B, D) NanA and (C) GM1 and concentrations was calculated using one-way




Articlebinding of PLY to HDL-2 as compared to binding to non-GM1-coated HDL-2 (Figure 2C). While no
binding of NanA to HDL-2 could be detected, regardless of the presence of GM1, the addition of
NanA increased binding of PLY to GM1-coated HDL-2 (Figures 2D and 2E). These results indicate
that the cleavage of terminal sialic acids by NanA exposes unesterified cholesterol on the surface of




ArticlePLY and NanA modify HDL particles
To validate the relevance of PLY interaction with HDL-2 surface unesterified cholesterol and the role of
NanA-mediated desialylation of HDL-2 in HDL function in vitro, we next analyzed the particles after incu-
bating them with the microbial molecules. The experiment included a control sample with the inhibitors,
liposomes and 2,3-didehydro-2-deoxy-N-acetylneuraminic acid (DANA) (Figure S2A), for PLY and NanA,
respectively (Braun et al., 1999). The size exclusion chromatographic (SEC) profile of the HDL-2 samples
showed that the major HDL-2 fractions eluted between 7.5 and 9.5 mL retention volumes, whereas
NanA and PLY eluted much later at 14.5-15 mL and 20-23 mL volumes (Figures 3A and S2B). PLY bound
to HDL was detected in the HDL-2 fractions (Figure 3B). The proteomic analysis of the HDL-2 samples
showed that PLY was abundant on those samples that were incubated in the presence of PLY (Figure 3C
and Table S2). The HDL-2 bound PLY was not functionally active, except in the sample that was incubated
in the presence of the PLY and NanA inhibitors (Figure S2C). This provided further evidence for the role of
HDL-2 in inhibiting PLY activity. Examination of the proteomic profiles revealed differences between the
HDL-2 sample incubated with only a buffer and the PLY- and NanA-incubated samples. The PLY and/or
PLY- and NanA-incubated samples showed depletion of PON-1 levels similarly as in the ex vivo assay.
Also, reduction in alpha-1-antitrypsin, apolipoprotein L1, apolipoprotein D, complement regulator plasma
protease C1 inhibitor, and clusterin was observed.PLY and NanA convert HDL from anti-inflammatory to pro-inflammatory and pro-atherogenic
particles
Due to the interactions of HDL-2 with PLY and NanA and the major modifications that were detected in
HDL-2 sialylation and protein content, we next studied whether these modifications could change the
anti-inflammatory role of HDL-2 to a dysfunctional and pro-inflammatory form. Modified HDL showed
reduced complement resistance, as the addition of preincubated HDL-2 to hirudin plasma resulted in
a significant increase in complement activation in the presence of PLY and NanA, while treatment of
plasma with HDL-2 in the absence of PLY and NanA treatment did not (Figure 4A). HDL-2 preincubated
with the negative control, LukS, did not increase complement activity (Haapasalo et al., 2019). Similarly,
the HDL-2 that had been separated by SEC after PLY and NanA treatment showed increased comple-
ment activity and C5a formation in serum when compared to non-treated HDL-2 as detected by increase
in the intracellular calcium in C5aR cells (Figure 4B) (Haapasalo et al., 2019). Pretreatment of C5aR-ex-
pressing cells with LukS, which is known to bind to C5aR and antagonize the effect of C5a (Figures
S3A and S3B) (Spaan et al., 2013), completely inhibited C5aR activation indicating specific activation
of C5aR cells through C5a formation induced by the PLY- and NanA-treated HDL-2. The PLY- and
NanA-modified HDL particles also activated IL-6 release in human umbilical vein endothelial cells, indi-
cating direct cell response to microbially modified HDL stimuli (Figure S3C) (Kaplanski et al., 1995). The
activity of HDL-2 was tested by examining its potential to remove cholesterol from cholesterol-labeled
THP-1 macrophages. Clear attenuation in cholesterol egress via PLY-NanA treated HDL2 was demon-
strated. The additional effect of NanA in the reduced cholesterol efflux was expected as glycosylation
has been shown to directly affect the functional properties of HDL (Sukhorukov et al., 2019) (Figure 4C).
To study the ability of the modified HDL to activate inflammatory responses on cells and escape from
oxidative stress, we measured release of IL-1b and IL-6 upon HDL stimuli and the presence of malondial-
dehyde (MDA) epitopes, the products of lipid peroxidation, on these same samples after incubation with
the THP-1 macrophages (Papac-Milicevic et al., 2016). Increased amounts of IL1-b, IL-6 released in the
supernatant, and MDA adducts in the HDL-2 sample incubated with PLY + NanA, PLY, or NanA indicated
cell response to the bacterially modified HDL and macrophage-mediated peroxidation of the modified
HDL (Figures 4D and 4E).
Further analysis of the HDL lipidome provided additional evidence for our functional data (Figure 4F) (Folch
et al., 1957). The lipidomes of HDL-2 particles treated with PLY and NanA showed relative increase in satu-
rated sphingomyelin (SM) and at the same time a decrease of polyunsaturated phosphatidylcholine (PC)
species, which in turn decreases membrane fluidity (Shaikh et al., 2006). Similarity, a relative increase of
saturated and a concomitant decrease of polyunsaturated species were detected in cholesterol ester
(CE) species of the HDL core. Because the cholesterol uptake by HDL is compromised by decreased fluidity
of the surface phospholipids (Davidson et al., 1995) and oxidative degradation may reduce the proportion
of polyunsaturated lipids in the HDL, the low cellular cholesterol efflux potential and increased aggregation
by PLY- and NanA-treated HDL (Figure 4G) is concordant with the lipidome changes.iScience 24, 102535, June 25, 2021 5
Figure 3. HDL modification by PLY and NanA in vitro
(A) Size exclusion chromatography (SEC) of HDL-2 after incubation of the particles alone or in the presence of PLY, NanA,
or PLY + NanA. PLY and NanA inhibitors, liposomes (LSs), and DANA were added to the control samples (HDL + PLY +
NanA + DANA + LS). The main HDL-2 peak shows fractions between 7.5 and 9.5 mL retention volumes that were collected
for experiments. See also Figures S2A and S2B.
(B) SDS-PAGE of HDL fractions that were collected after SEC at protein concentration of 16 mg/mL. PLY is shown as a
72.8 kDa band. Major lipoprotein of HDL, ApoA-I, is shown as a 28.3-kDa band. HDL control sample showing proteins
present in HDL-2 sample before SEC.
(C) HDL-2 samples analyzed byMS/MS comparing the protein profile of the HDL-2 samples after SEC. See also Figure S2C
and Table S2. Numbers are shown as the percentage of peptide spectrum matches (PSMs) of all identified proteins with a
score of >10 or PSMs >4 in the HDL-2 sample. Reduction in protein content in PLY- and/or NanA-treated HDL samples





Despitemore than two decades of extensive research, no specific pathogen has been conclusively linked to
atherosclerosis in humans (Lathe et al., 2014). Recent studies, however, have identified Porphyromonas gin-
givalis in the brain of patients with Alzheimer disease and in arteries of patients with cardiovascular disease,
suggesting that the toxic proteases from the bacterium could be involved in development of these6 iScience 24, 102535, June 25, 2021
Figure 4. Effect of PLY and NanA on HDL function
(A) Complement activation as measured by the amount of soluble C5b-9 formation in hirudin plasma with (100 mg/mL of HDL) or without (no HDL) HDL
particles that were incubated in the presence or absence of PLY and/or NanA. LukS was used as a negative control for complement activation in plasma.
(B) Calciummobilization of HEK-C5aR cells in the presence of HDL-2 particles that were incubated in the presence or absence of PLY and NanA. Specificity of
C5a-mediated calcium mobilization was analyzed using LukS. See also Figures S3A and S3B.
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(C) Cholesterol efflux from PMA-activated and cholesterol-labeled THP-1 cells in the presence of HDL-2 particles that were isolated by SEC. The samples
were HDL ctrl (= HDL not run through SEC), HDL only (HDL), HDL + PLY, HDL + PLY + NanA, HDL + PLY + NanA + DANA + liposomes (LS), and HDL + NanA.
Cholesterol efflux is represented as the percentage of efflux elicited in four hours. The non-specific efflux background without HDL was subtracted from the
samples.
(D) Release of IL-1b and IL-6 by activated THP-1 cells when exposed to HDL and PLY, NanA + PLY, and NanA-modified HDL particles.
(E) The presence of MDA epitopes on HDL-2 after a four-hour incubation with activated THP-1 macrophages from the efflux assay. LS and DANA (HDL +
PLY + NanA + DANA + LS) were included in the experiment to neutralize the effect of PLY and/or NanA.
(F) HDL-2 samples analyzed by ESI-MS/MS to compare the lipid diversity of the HDL-2 samples after SEC. The results are expressed as fold change values
obtained by dividing the molar percentage of the lipid structural category in the HDL with PLY and NanA by the corresponding values in ctrl HDL. For SM,
categories long or very long included species with 15‒18 or 23‒25 acyl carbons, respectively.
(G) Aggregation (arrow) of HDL particles in the presence or absence of PLY and PLY + NanA shown by lipid staining after native PAGE. LukS is used as
negative control for aggregation and BSA as a size standard (7.1 nm) and negative control for lipid staining. Non-aggregated HDL is shown between the
dashed lines. Statistical significant (p < 0.05) differences between samples in (A)–(E) were determined using one-way ANOVA followed by Dunnet’s non-




Articlediseases (Dominy et al., 2019). In human clinical specimens, concentrations of cytolysins can be very high
ranging from 0.33 mg/mL to 399 mg/mL (Badiou et al., 2010), and, in pneumococcal infections, these can
rapidly increase through the release of PLY as result of pneumococcal autolysis (Jacques et al., 2020; Mell-
roth et al., 2012).
As HDL is capable of neutralizing the endotoxicity of LPS, similarly, we showed that it also inhibits the he-
molytic activity of PLY (Levine et al., 1993). While LPS is carried and neutralized by a specific LPS-binding
protein on HDL (Wurfel et al., 1994), the binding of PLY most likely requires lipid raft microdomains rich
in unesterified cholesterol (Taylor et al., 2013). Such dynamic and small raft domains were suggested to
form the surface of LDL (Hevonoja et al., 2000). Enriching HDL with PLY may require a larger total area
of the raft domains, which are more likely present in the larger andmore lipid-rich HDL-2 than in the smaller
HDL-3 (Chapman, 1986). These raft domains would increase themembrane proportions of both cholesterol
and SM having a molecular structure compatible with cholesterol (Slotte, 2016; Yetukuri et al., 2010).
Gangliosides are sialic-acid-containing glycosphingolipids found on HDL (Siegel et al., 2014). Of these,
GM1 has a crucial role in protecting the host from the immune system (Cutillo et al., 2020). Herein, we
demonstrate that sialic acids have a role in protecting HDL from PLY and possibly also from complement
as NanA reduced HDL complement resistance. In addition, the absence of clusterin in the PLY and NanA-
modified HDL correlated with the formation of soluble complement components in plasma. Clusterin is a
complement regulator found on HDL. It has been suggested to inhibit formation of terminal complexes of
C5b-9 and regulate lipid transport (Jenne et al., 1991). Importantly, the increase in complement activity also
resulted in activation of C5aR on cells and release of IL-1b and IL-6. This indicates that the presence of PLY-
and NanA-modified HDL could lead to activation of cells present in atherosclerotic intima such as endothe-
lial cells and may thereby activate coronary plaques and trigger chronic inflammation (Oksjoki et al., 2007).
HDL has been found to contain a diverse set of enzymatically active proteins, hydroxylated derivatives of
polyunsaturated fatty acids, and hydroperoxides, and although HDL is regarded as anti-oxidative and anti-
inflammatory, during the acute phase reaction, oxidative and inflammatory reactions take over (Lemes
et al., 2020; Navab et al., 2001; Vaisar et al., 2007). Our finding that PLY-modified HDL contains a high con-
centration of MDA suggests dysfunction of the particle and enhancement of oxidative reactions (Shao
et al., 2010). Thus, oxidative degradationmay be an additional mechanism reducing the proportion of poly-
unsaturated lipids in HDL-2 after treatment with PLY, NanA, or both. Once the proportion of polyunsatu-
rated PC decreases, then the remaining oxidation-resistant saturated PCs in HDL increase, which was
evident in the treated HDL-2 of this study. Since oxidative reactions are chain reactions, the HDL core lipids
are also affected, seen as the reduction of polyunsaturated CE and consequent relative increase in the satu-
rated CE. As shown here, the modifications of the HDL lipidomes by PLY and NanA have consequences for
the particle aggregation susceptibility. Experiments with LDL have shown that increased levels of SM, and
especially the long chain saturated species of SM, associate with increased LDL aggregation susceptibility.
In contrast, increased levels of PC and especially the polyunsaturated PC species associate with a low ag-
gregation propensity (Ruuth et al., 2018).
PON-1 and glycosylphosphatidylinositol-specific phospholipase D have been shown to protect HDL from




Articlelevels of PON-1 in HDL-2 both in vitro and ex vivo supports previous findings that modified HDL particles
are susceptible to oxidative stress (Dousset et al., 1994). The proteome profile of HDL isolated from the
ex vivo assay also showed reduction in the presence of apolipoproteins and increase of acute phase pro-
teins such as serum amyloid A-1 (SAA) and transthyretin. It has been shown that HDL-containing SAA loses
its anti-inflammatory properties and becomes proinflammatory. Moreover, an increase of SAA in HDL leads
to detachment of HDL major protein, apoA-I from the particle (Vaisar et al., 2015), which is consistent with
our MS data. Detachment of apoA-I would lead to attenuated cholesterol efflux via the ABCA1 receptor on
macrophages due to reduced interaction between apoA-I and ABCA1. In addition, transthyretin has been
shown to exhibit protease function against apoA-I (Sharma et al., 2019).
Understanding the role of microbial molecules in promoting acute inflammation is essential. However, as
shown in this study, these molecules also cause spatial and functional changes in circulating lipoproteins
that may trigger the inflammatory response indirectly. Our finding of such a molecular mechanism using
human HDL and the role of microbial molecules in triggering chronic inflammation in atherosclerosis could
advance development of therapies to prevent this disease at a very early stage.Limitations of the study
Rabbits have a lowHDL cholesterol profile, similar to humans, and have been used to study diseasemechanisms
of atherosclerosis (Yin et al., 2012). However, the human specificity of PLY observed here, andby others, indicates
that the 3b-hydroxyl group of cholesterol alone does not explain PLY host tropism (Shewell et al., 2014, 2020).
Notably, NanA targets the terminal sialic acid N-acetylneuraminic acid (Neu5Ac), which is abundant in human
cells but not in other mammalian cells (Hentrich et al., 2016). As 90% of human HDL glycoproteins are sialylated,
current transgenic animal models expressing human glycoproteins would be mainly expressing N-glycolylneur-
aminic acid (Neu5Gc) (Huang et al., 2014; Krishnan et al., 2017). Therefore, due to the lack of suitable animal
models, this study was unable to provide explanation of PLY function in vivo.STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following:
d KEY RESOURCES TABLE
d RESOURCE AVAILABILITYB Lead contact
B Materials availability
B Data and code availability
d EXPERIMENTAL MODEL AND SUBJECT DETAILS
B HDL isolation




B Preparation of liposomes
B Binding of PLY to GM1 coated HDL
B Removal of sialic acids from HDL by NanA
B Neuraminidase activity assay
B Size exclusion chromatography (SEC)
B Mass spectrometric analysis for protein composition
B Ex vivo binding assay
B Complement activation on HDL particles
B Calcium mobilization assay
B Cholesterol efflux assay
B Measuring cellular release of cytokines
B Measuring Malondialdehyde (MDA) adducts on HDL
B Mass spectrometry analyses of HDL lipid composition
B Native PAGE and lipid staining





Supplemental information can be found online at https://doi.org/10.1016/j.isci.2021.102535.
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Data and code availability
The published article includes all data generated or analyzed during this study.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
HDL isolation
HDL samples were prepared from freshly isolated plasma of normolipidemic healthy volunteers obtained
from the Finnish Red Cross Blood Service by sequential flotation ultracentrifugation using potassium-bro-
mide for density adjustment as previously described using a referencemethod from (Havel et al., 1955). The
volunteers included both genders between ages 25-60 years old. The methodology and the quality control
of the preparations were as follows: Plasma VLDL (d < 1.006 g/mL), LDL (1.019 < d < 1.063 g/mL), total HDL
(1.063< d < 1.210 g/mL), HDL-2 (1.063 < d < 1.125 g/mL) and HDL-3 (1.125 < d < 1.210 g/mL). All steps were
done in KBr-salt solution to avoid any artificial chemical modifications. The purity of the HDL-2 fraction was
analyzed with regard to apoB-100 using human apoB-100 ELISA with apoB-100 detection sensitivity of
about 6 ng/ml (Abcam, Cambridge, UK). The isolated HDL-2 was practically devoid of apoB-100 as the con-
centration of apoB-100 in the preparation was 8 ng/ml. The measured total protein and lipid composition
of the isolated HDL-2 (as mass%) were as follows: protein 41%, phospholipids 27%, cholesterol esters 24%,
free cholesterol 5% and triglycerides 3%. Isolated HDL-2 was extensively dialyzed against phosphate buff-
ered saline (PBS pH 7.4) before analysis (Havel et al., 1955).
Isolation of plasma and red blood cells
Blood was drawn into hirudin tubes (Roche Diagnostics, Mannheim, Germany) from healthy human volun-
teers after informed written and signed consent (Ethical Committee decision HUS/135/2020, Hospital dis-
trict of Helsinki and Uusimaa). The volunteers included both genders between ages 25-60 years old. To
separate the plasma from blood cells the sample was centrifuged at 300 3 g for 10 min at room temper-
ature. Collected cells were washed twice with phosphate buffer saline (PBS pH 7.4) and 1% red blood
cell suspension was prepared in PBS.
METHOD DETAILS
Hemolysis assay
The isolated red blood cells were incubated in round bottom 96-well polystyrene plates (Nunc, Roskilde,
Denmark) in PBS with different concentrations of recombinant pneumolysin (PLY) (Cusabio technology LLC,
Houston, TX) and in the presence or absence of 800 nM of a recombinantly expressed S. pneumoniaeNanA
neuraminidase fragment containing the functional C-terminal domain (amino acids 330-777) (Syed et al.,
2019). Incubation was done in an orbital rotator for 30 min at 37 C. Red blood cells were pelleted by centri-
fugation at 300 3 g for 10 min, and 30 ml of the supernatant was diluted with 70 ml PBS. Hemolysis was de-
tected by measuring the absorbance at 405 nm with iEMS Reader MF (Labsystems Diagnostics Oy, Vantaa,
Finland). Inhibition of lysis by HDL was measured by incubating increasing concentrations of HDL-2
(0-100 mg/ml) with 10 nM of PLY and 1% red blood cells in PBS with or without 800 nM of NanA in round
bottom 96-well polystyrene plates (Nunc). Hemolysis was measured at 405 nm as described above.
Increasing concentrations of Saponin (1.52 3 10-5% to 0.1%, Acros Organics, Fair Lawn, NJ) in Roswell
Park Memorial Institute (RPMI) 1640 medium (Gibco) were used as a positive control for hemolysis, while
liposomes were used to analyze the role of cholesterol in PLY inhibition.
Permeability assay
THP-1 monocyte-derived macrophages obtained from American Type Culture Collection (ATCC, Virginia,
USA) were cultured in RPMI medium supplemented with penicillin, streptomycin, Glutamax and 10% (v/v)
fetal bovine serum at 37 C in the presence of 5% CO2. Cells were centrifuged at 3003 g for 10 min at 4 C.
The supernatant was removed, and the pellet was resuspended in RPMI medium supplemented with 0.05%
human serum albumin (Sigma Aldrich, St. Louis, MO). Cells were used at a concentration of 1 x 106 cells/ml.
The nucleus staining dye 40,6-diamidino-2-phenylindole (DAPI) (Invitrogen, Carlsbad, CA) was added to the
cells (1 mg/ml). HDL particles (suspended in PBS pH 7.4) were prepared as mentioned before. THP-1 cells




Articleabsence of the recombinant NanA (800 nM) in 96 well round clear-bottom plates (Nunc) at 37 C for 30 min
with mild shaking. 100 nM of Staphylococcus aureus toxin component LukS was included as a negative con-
trol (Haapasalo et al., 2019). Incubated cells were washed with RPMI medium with fatty acid free 0.05% hu-
man serum albumin (Sigma) (RPMI-HSA) medium at 300 3 g for 10 min at room temperature. The superna-
tant was discarded, and cells were resuspended in 1% paraformaldehyde (v/v) in RPMI-HSA medium.
Events were acquired on BD LSR Fortessa flow cytometer (laser 405 nm filter 450/40). The signal threshold
for cell permeability was set by measuring fluorescence of cells incubated with DAPI alone, and the fre-
quency of permeable cells compared to the parent population was determined using FlowJo 10.1r5
(FlowJo LLC, Ashland, Oregon).
Preparation of liposomes
Liposomes were prepared using 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and unesterified
cholesterol at a 7:3 ratio and following thin film protocol (Briuglia et al., 2015; Jimah et al., 2017). Briefly,
to formulate 1 mM liposomes, 700 mM of DSPC and 300 mM of cholesterol were prepared by dissolving
appropriate amounts in 2 ml chloroform in a round bottom flask. The mixture was then evaporated in a ro-
tary evaporator for 30 min at 35C to obtain a dry lipid film. This film was further dried in a vacuum oven for
1 h at 40 C. After overnight incubation, the liposomemixture was sonicated using probe sonicator for 3 min
at intervals. The multilamellar vesicles were then extruded at 90 C with polycarbonate filters (100 nm pore
size) using Avanti Polar Lipid extruder kit (Sigma-Aldrich, St. Louis, MO) to obtain unilamellar vesicles.
Finally, the vesicles were concentrated, and the concentrated liposome solution was washed with ultrapure
water and centrifuged (3 times) until a clear solution was collected in the filtration tube. Then, 20 ml of the
liposome concentrate was added to 700 ml of PBS in a cuvette and the hydrodynamic size was measured
using dynamic light scattering (DLS) instrument. The purified liposomes displayed a hydrodynamic size
of 172 nm with a polydispersity index (PDI) of 0.08.
Binding of PLY to GM1 coated HDL
To analyze binding of PLY and NanA to HDL-2, 80 mg/ml of HDL particles were coated on 96-well plates
(SpectraPlate-96 HB, PerkinElmer, Waltham, MA) in bicarbonate buffer (pH 9.6) overnight at 4 C. Fatty
acid free bovine serum albumin (Biowest, Rue du Vieux Bourg, Nuaillé, France) (BSA) coated wells were
used to control nonspecific binding of the proteins to the wells. Wells were washed once with PBS where
after the coated plates were incubated with increasing concentrations of PLY and NanA at 37 C for 1 h.
Wells were washed with PBS three times and blocked with 3% BSA in PBS for 2 h at 37 C. After one
wash with PBS, the wells were incubated with 0.4 mg/ml penta-His antibody (Qiagen, Hilden, Germany)
in PBS with 0.05% BSA (BSA/PBS) at 37 C 1 h. Wells were washed three times with PBS and incubated
with 1:2000 dilution of HRP conjugated anti-mouse IgG antibody (Jackson ImmunoResearch Laboratories,
West Grove, PA) in 0.05% BSA/PBS at 37 C for 1 h. After three washes with PBS, o-phenylenediamine di-
hydrochloride (OPD) substrate (Dako Corporation, Carpenteria, CA) was added according to manufacturer
instructions. The reaction was stopped with 0.5M H2SO4 and absorbance was measured at 492 nm. Binding
was calculated after subtracting the background absorbance of the BSA background control.
To analyze binding of PLY to different HDL samples (human HDL, rabbit HDL, HDL-2 and HDL-3), 80 mg/ml
of each HDL sample was coated on 96-well plates (SpectraPlate-96 HB) in bicarbonate buffer (pH 9.6) over-
night at 4 C. BSA coated wells were used to control nonspecific binding of the proteins to the wells. Wells
were washed once with PBS and blocked with 3% fatty acid free BSA (Biowest) in PBS for 2 h at room tem-
perature. Wells were washed once with PBS and then incubated with increasing concentrations of PLY at 37
C for 1 h. After three washes with PBS, the wells were incubated with 1 mg/ml of rabbit anti-PLY antibody
(Abcam) in 0.05% BSA/PBS at 37 C 1 h. Wells were washed three times with PBS and incubated with 1:2000
dilution of HRP conjugated anti-rabbit IgG antibody (Jackson ImmunoResearch Laboratories, West Grove,
PA) in 0.05% BSA/PBS at 37 C for 1 h. After three washes with PBS, OPD substrate (Thermo Fischer Scien-
tific) was added according to manufacturer’s instructions. The reaction was stopped with 0.5M H2SO4, and
absorbance was measured at 492 nm.
Because of the important anti-inflammatory role of monosialotetrahexosylganglioside (GM1) and the high
affinity between lipoproteins and ganglioside hydrophobic ceramide moiety (Rebbaa and Portoukalian,
1995), HDL particles were coated with GM1 to study the interaction of sialylated carbohydrates with micro-
bial molecules. HDL-2 particles were incubated with increasing concentrations of GM1 (0-10 mg/ml) for 1 h




Articleat 37 C and washed three times with PBS followed by blocking with 3% BSA/PBS as described above. To
study the effect of sialic acid removal by NanA in PLY binding to HDL the HDL-2 coated wells were washed
once with PBS, and incubated with or without 10 mg/ml of GM1 for 1 h at 37 C. After three washes with PBS,
wells were incubated with increasing concentrations of NanA (0-800 nM) for 1 h at 37 C. Next, wells were
incubated with 30 nM of PLY or PBS for 1 h at 37 C, and washed again three times with PBS before blocking,
incubation with antibodies and detection as described above.
Removal of sialic acids from HDL by NanA
To detect removal of sialic acids from HDL, Maackia Amurensis Lectin II (MAL-II) (Vector Labs, Burlingame,
CA) was labeled with NT-647 dye (NT647-MALII) following the manufacturer instructions (NanoTemper
Technologies GmbH, München, Germany). NT647-MAL-II was diluted in microscale thermophoresis
(MST) buffer (25 mM HEPES, gibco; 150 mM KCl; 0.01% NaN3; 0.01% Tween-20) and was centrifuged (16
000 3 g, 5 min, 4 C) to remove any aggregates. HDL-2 was diluted (1:1) in PBS in a 16 step dilution series
and constant concentration of labeled NT647-MAL-II was added to the samples. Finally, samples were
transferred to premium capillaries (NanoTemper) for MST measurement using Monolith NT.115Pico
(NanoTemper) instrument. EC50 values were obtained from the MST data using the Hill equation in MO.Af-
finity Analysis software (NanoTemper).
Release of terminal sialic acids from HDL surfaces was detected using modified thiobarbituric acid (TBA)
assay. The HDL (470 mg/ml) particles were incubated with NanA for 30 min at 37 C in PBS. The chromo-
phore was developed, and free sialic acids were quantified relative to the absorbance of the chromophore
at 550 nm, following the previously published protocol (Warren, 1959).
Neuraminidase activity assay
To analyze the effect of the sialic acid analogs on NanA activity, 4-Methylumbelliferyl N-acetyl-a-D-neura-
minic acid (MUAN) (Carbosynth) fluorescence substrate was used, and the assay wasmodified from the pre-
viously published method (Potier et al., 1979; Syed et al., 2019). NanA (5 nM) was incubated with MUAN
(0.003%) in sodium acetate buffer (pH 7) for 5 min at 37 C in 96-well black clear-bottom microplates (Per-
kin-Elmer, Waltham, MA, US) in the presence of increasing concentrations (0-800 nM) of 30-Sialyllactose
(3SL) (Carbosynth, Compton, Berkshire, UK) or 2,3-didehydro-2-deoxy-N-acetylneuraminic acid (DANA)
(Carbosynth). NanA activity was checked by measuring the release of the fluorophore by measuring
355 nm (excitation) and 460 nm (emission) in the Hidex Sense microplate reader (Hidex, Turku, Finland).
Size exclusion chromatography (SEC)
HDL particles (1.25 mg/ml) were incubated in the presence or absence of NanA (10 mM), in the presence or
absence of PLY (1.7 mM), and in the presence or absence of liposomes and DANA (20 mM) (Carbosynth), in
LoBind tubes (Eppendorf, Hamburg, Germany) for 20min at room temperature. Next, the samples were run
through SEC column (Superdex 200 10/300 GL column Global Life Sciences Solutions LLC, Marlborough,
MA, United States) at 0.5 ml/min flow rate in PBS. Fractions of 300 ml were collected, and the HDL-2 fractions
from 8.3-10.0 ml were pooled and stored immediately at -80 C until further analysis. The peaks from SEC
were run on Mini-PROTEAN TGX Stain-Free precast gels 4-20% in non-reducing conditions (Bio-Rad Lab-
oratories, Hercules, CA) at 120 V, 60 min, stained with silver stain and imaged with Gel Doc XR+ system us-
ing silver stain protocol in Image Lab software (Bio-Rad). Protein concentrations of the samples were
measured with the Bicinchoninic acid assay (BCA) (Pierce Biotechnology, Rockford, Il, US) according to
manufacturer instructions. To estimate the amount of HDL in the assays, the concentrations of HDL samples
are expressed as the equivalent concentration (mg/ml) or weight (mg) of protein.
Mass spectrometric analysis for protein composition
The proteomic analyses were performed at Helsinki University proteomics unit. A total of 5 mg of each iso-
lated HDL-2 fraction was purified by reversed-phase chromatography columns (C18 material, eluted with
50% CH3CN, 0.1% TFA) (PMID: 23602568). The dried peptides were reconstituted (1% CH3CN, 0.1%
TFA), and theMS analysis was performed on an Orbitrap Elite ETDmass spectrometer (Thermo Fischer Sci-
entific) using Xcalibur Version 2.7.1 coupled to a Thermo Scientific nLCII nanoflow HPLC system. Peak
extraction and subsequent protein identification were achieved using Proteome Discoverer software
(Thermo Fischer Scientific). Calibrated peak files were searched against the human component of the Uni-




ArticlewereG15 ppm andG0.8 Da, respectively. For peptide identification, a stringent cut-off (1% false discovery
rate) was used.
Ex vivo binding assay
Hirudin anticoagulated blood was incubated in the presence or absence of 200 nM PLY or 200 nM PLY and
1.2 mM NanA for 1 h at 37 C in a rotator. Plasma was separated from blood by centrifugation (10 min
1,000 3 g) and HDL samples were prepared by sequential flotation ultracentrifugation using potassium-
bromide for density adjustment as described above. The HDL proteomes were analyzed by MS/MS and
western blotting (WB). For WB 40 ml of the samples and 50 ng of PLY were run on SDS-PAGE using Mini-
PROTEAN TGX Stain-Free precast gels (Bio-Rad) under non-reducing conditions for 75 min at 150 V.
The proteins were transferred (iBlot, Thermo Fisher Scientific) to nitrocellulose membrane (iBlot 2 Trans-
fer Stack, Invitrogen) and blocked with 3% milk/PBS. The membrane was then incubated with 0.4 mg/ml of
mouse anti-penta-His antibody (Qiagen, Hilden, Germany) in 0.3% milk/PBS for 1 h at 37 C and after
washing with PBS with 1:5000 dilution of IRDye 800CW Donkey anti-mouse IgG Secondary Antibody
(LI-COR) for 1 h at 37 C in 0.3% milk-PBS. The membrane was washed with PBS and imaged using
Odyssey CLx Imaging System (LI-COR).
Complement activation on HDL particles
HDL-2 particles were incubated in the presence or absence of NanA (800 nM) and in the presence of PLY
(2.5, 42 or 660 nM) for 30 min at 37 C. Controls without HDL, incubated with NanA (800 nM) and PLY (2.5, 42
or 660 nM) were included tomeasure the background complement activation. S. aureus toxin LukS (660 nM)
in the presence and absence of NanA fragment (800 nM) was included as a negative control (Haapasalo
et al., 2019). Next, 1:5 volume of 50% hirudin plasma diluted in PBS was added to the samples and
incubated for 30 min at 37 C. Complement activation was stopped immediately by adding 10 mM
EDTA. Samples were stored at -20 C until further use. Complement activation was measured by quanti-
fying the formation of the soluble C5b-9 (sC5b-9) using a Quidel ELISA kit (San Diego, CA). Samples
were diluted 1:40 in the provided dilution buffer, and manufacturer instructions were followed.
Calcium mobilization assay
Preparation of Human Embryonic Kidney (HEK) 293T cells (Invitrogen), stably expressing G protein Ga16
and human C5aR has been described before (Haapasalo et al., 2019). HEK-C5aR cells (5 x 106 cells/ml)
were loaded with 2 mM Fluo-4-Am ester (Abcam) in HBSS media (Gibco) in the presence of 0.05% human
serum albumin (Sigma), 10 mMHEPES (Gibco) and 2.5 mM Probenecid (Sigma) for one hour at 37 C, gently
agitating and protected from light. Next, cells were washed with the same buffer and diluted to 5 x 105
cells/ml with or without 300 nM of LukS antagonist. The PLY and NanA or buffer treated and SEC isolated
HDL samples were incubated in 10% normal human serum for 30 min at 37 oC at a protein concentration of
17 mg/ml and placed immediately on ice before analysis. C5aR activity was measured by running the cells
(2.5 x 105 cells /ml) in flow cytometry for 30 seconds without stimulus and 120 seconds after adding the
stimulus; C5a (Abcam) or diluted HDL sample incubated with 10% serum (Figure S3A). C5aR activity was
calculated by subtracting the mean fluorescence intensity of cells before stimulus from mean fluorescence
intensity of cells after the stimulus.
Cholesterol efflux assay
THP-1 cells (100 000 cells/well in a 96-well plate) were activated with 100 nM Phorbol 12-myristate 13-ace-
tate (PMA) (Sigma-Aldrich, St. Louis, MO) in RPMI medium for 72 h and cultured at 37 C in 5% CO2 atmo-
sphere. Cholesterol efflux was determined using a cell-based Cholesterol Efflux Assay kit (Abcam,
Cambridge, UK) according to manufacturer’s instructions. Activated cells were labeled with fluorescent
cholesterol for 16 h and washed with the RPMI-HSA medium. A total of 5 mg protein weight of the treated
HDL samples were added to the culture of cholesterol-labeled cells. The HDL treated samples were 1) HDL
only, 2) HDL + PLY, 3) HDL + PLY + NanA, 4) HDL + PLY + NanA + DANA + liposomes and 5) HDL + NanA.
These were prepared as described in SEC section: HDL particles (1.25 mg/ml) were incubated with NanA
(10 mM), PLY (1.7 mM), liposomes and DANA (20mM) for 20minutes at room temperature. Specific inhibitors
of PLY and NanA, liposomes (LS) and DANA (HDL+PLY+NanA+DANA+LS) were included into the exper-
iment to neutralize the effect of PLY and NanA. The Cholesterol efflux of HDL (HDL ctrl.) that was not run
through SEC was also measured. Incubation of the HDL treated samples with cholesterol labeled cells was




Articlethe solubilized donor cells at 485 nm (excitation) and 520 nm (emission) in the Hidex Sense microplate
reader (Turku, Finland). Total cellular efflux mediated by HDL was calculated by the ratio between fluores-
cence intensity of media and fluorescence intensity of cell lysate plus media after subtraction of non-spe-
cific efflux background without HDL (average+/-SD being 16.1+/-1.5%) and presented as %.
Measuring cellular release of cytokines
THP-1 monocyte-derived macrophages (ATCC) were cultured in RPMI medium supplemented with peni-
cillin, streptomycin, 25 mM HEPES, 2 mM Glutamax and 10% (v/v) fetal bovine serum. Human umbilical
vein endothelial cells (HUVECs, a kind gift from Mikko Helenius, University of Helsinki, Helsinki, Finland)
were grown using EndoGRO-LS complete media kit according to manufacturer’s instruction (SCME001
from Merck-Millipore) as confluent monolayers at density of 150 000 cells/well in 24-well tissue culture
plates (Greiner) at 37 C in the presence of 5% CO2. THP-1 cells (400 000 cells/well) were differentiated us-
ing 150 nM PMA (Sigma-Aldrich, St. Louis, MO) for 72 hours in 24-well tissue culture plates. Differentiated
THP-1 cells were cultured in fresh media overnight. Cells were kept in serum free media for 20 minutes
before samples were added. To measure the cellular release of IL-1b and IL-6 by both cell types a total
of 0.94 mg of the treated HDL samples were added to the cells in 250 ml volume of serum free culture media
and were incubated for 20 hours. The incubation media was collected, and the concentrations of IL-1b and
IL-6 were measured by ELISA assays (Human IL-1b DuoSet ELISA, cat. DY201; Human IL-6 DuoSet ELISA,
cat. DY206; and Human TNF-alpha DuoSet ELISA cat. DY210) following the manufacturer’s instructions
(R&D Systems).
Measuring Malondialdehyde (MDA) adducts on HDL
As an indicative biomarker of the oxidative stress, we assessed the presence of malondialdehyde (MDA)
adducts on HDL. The supernatant from activated THP-1 macrophages that had been incubated with fluo-
rescently labeled cholesterol was stored at -20 C in 96 well round bottom plates (Nunc) until further use.
The MDA epitopes were detected on the HDL suspended in this supernatant using a commercial Oxidized
HDL Assay Kit (MDA-HDL, Human) from Abcam according to manufacturer’s instructions. This ELISA kit
captures MDA epitope containing particles and detects ApoA-I from samples.
Mass spectrometry analyses of HDL lipid composition
Total lipids of the isolated HDL particles were extracted for lipid mass spectrometry (MS) with the method
previously described (Folch et al., 1957). Aliquots of the lipid extracts were dissolved in chloroform/meth-
anol (1:2 v/v) and spiked with a mixture of internal lipid standards containing representatives for all the lipid
classes analyzed. Just prior toMS, NH4OHwas added to aliquots of the sample extracts to give 2% solution,
which supported ionization and prevented sodium adduct formation. The samples were introduced via a
syringe pump into the electrospray ionization (ESI) source of a triple quadrupole MS (Agilent 6410 Triple
Quad LC/MS; Agilent Technologies, Inc., Santa Clara, USA) at a flow rate of 10 ml/min. MS/MS precursor
ion scans of m/z 184 and m/z 369 were used to detect phosphorylcholine-containing phospholipid species
(PC and SM) and CE species, respectively. The ESI-MS/MS instrument was set to a source temperature of
250 C and collision energies optimized for each lipid class (13-30 eV) were used. Nitrogen was used as the
collision, nebulizing (40 psi), and drying gas (3 l/min). Data analysis of the mass spectra was performed by
using MassHunter Workstation qualitative analysis software (Agilent Technologies, Inc.), and the individual
lipid species were quantified and converted to molar percent data using the internal standards and Lipid
Mass Spectrum Analysis (LIMSA) software, which has an inbuilt deisotoping routine that will automatically
correct for an overlap of isotope peaks (Haimi et al., 2006). The results are expressed as fold change values
obtained by dividing the molar% of the lipid structural category in the HDL with PLY and NanA by the cor-
responding values in untreated HDL.
Native PAGE and lipid staining
Blood was collected in EDTA tubes (BD Vacutainer) and HDL was isolated from EDTA anticoagulated serum
as described above. HDL in a protein concentration of 100 mg/ml was incubated in PBS (pH 7.4) in the pres-
ence of 1.4 mM pneumolysin (Cucabio) and/or in presence of 1 mM NanA, or 1.4 mM LukS toxin in 96-well
round bottom plates at 37 C for 1 hour. 2 x native sample buffer (62.5 mM Tris-HCl, pH 6.8, 40% glycerol,
0.01% bromophenol blue) was added in a 1:1 ratio to the samples. A total of 5 mg of HDL protein content in
the presence or absence of 1.2 mg of LukS, or 3 mg of pneumolysin in the presence or absence of 1.4 mg of




Article(Biotop, Turku, Finland) was run on the same gel as a 7.1 nm size standard and as a negative control for
specific labeling of lipids. Gel was run for 1 hour at 100 V in 25 mM Tris, 192 mM glycine buffer, pH 8.3,
and imaged with Gel Doc XR+ system using stain-free gel protocol in Image Lab software (Bio-Rad). To
detect the lipids, the gel was stained with the Sudan Black B (Merck) dye overnight at room temperature.
Briefly, 500 mg of Sudan Black B was dissolved in 20% acetone, 12.5% acetic acid dissolved in ddH2O. The
solution was stirred for 30 min at room temperature and added to the gel and incubated overnight at room
temperature. The following day the Sudan Black B staining solution was removed, and the gel was de-
stained by incubating with the destaining solution (15% acetic acid, 20% acetone dissolved in ddH2O)
for 15 min. The procedure was repeated three times before the gel was imaged with Gel Doc XR+ system
using Coomassie blue stain protocol in Image Lab software.QUANTIFICATION AND STATISTICAL ANALYSIS
Experiments were performed using at least three biological replicates. For statistical analyses SPSS pack-
age was used (SPSS version 24 IBM Statistics). First, Kolmogorov-Smirnov normality test was used to
analyze whether variables were normally distributed. Statistical significance between two samples was
analyzed using Mann-Whitney U test. For multiple comparisons and samples with unequal variances,
one-way ANOVA supplemented with Dunnett’s post hoc test was used (SPSS version 24 IBM Statistics).
Standard p-value threshold of <0.05 was used to indicate statistical significance.iScience 24, 102535, June 25, 2021 21
